Walgreens Raises More Than $1.3 Million in 2012 Campaign to Support Type 1 Diabetes Research

  Walgreens Raises More Than $1.3 Million in 2012 Campaign to Support Type 1
                              Diabetes Research

PR Newswire

NEW YORK, Nov. 16, 2012

NEW YORK, Nov.16, 2012 /PRNewswire-USNewswire/ --Walgreens, the nation's
largest drugstore chain, and JDRF, the world's largest charitable funder of
research toward curing, treating, and preventing type 1 diabetes (T1D) and its
complications, today announced that Walgreens community-based programs helped
raise more than $1.3 million in 2012 for JDRF. The year marked the 21^st
anniversary of Walgreens' participation in JDRF's nationwide campaign to raise
funds for research to put an end to the disease that affects as many as 3
million Americans.

During the month of July, as part of the Walgreens Way to Well Commitment™,
customers at more than 7,500 Walgreens stores could make donations of $1 or
more at checkout. This effort raised more than $1.3 million for JDRF.

"Walgreens is proud to support JDRF and we're thankful to our customers and
employees who have helped raise more than $18 million toward type 1 diabetes
efforts over the past 20 years," said John Gremer, director of community
affairs for Walgreens. "Through the Walgreens Way to Well Commitment™, we aim
to help improve people's everyday health through education and early detection
of today's leading diseases -- cancer, diabetes, and heart disease."

"The support that Walgreens provides JDRF year after year is remarkable," said
Jeffrey Brewer, president and CEO of JDRF. "For more than two decades, their
commitment to JDRF's mission has helped fuel critical research toward
preventing, better treating, and curing type 1 diabetes. We value our
collaboration with Walgreens and look forward to the continued growth of type
1 diabetes research progress."

About T1D

In T1D, a person's pancreas stops producing insulin, a hormone that enables
people to get energy from food. People with T1D need to test their blood sugar
and give themselves insulin (with injections or an insulin pump) multiple
times every day, and carefully balance insulin doses with eating and daily
activities throughout the day and night. However, insulin is not a cure for
diabetes, and even with that intensive care, a significant portion of the day
is still spent with either high or low blood sugar, placing people with T1D at
risk for devastating complications such as heart attack, stroke, blindness,
and amputation.

About Walgreens

As the nation's largest drugstore chain with fiscal 2012 sales of $72 billion,
Walgreens (www.walgreens.com) vision is to become America's first choice for
health and daily living. Each day, Walgreens provides more than 6 million
customers the most convenient, multichannel access to consumer goods and
services and trusted, cost-effective pharmacy, health and wellness services
and advice in communities across America. Walgreens scope of pharmacy services
includes retail, specialty, infusion, medical facility and mail service, along
with respiratory services. These services improve health outcomes and lower
costs for payers including employers, managed care organizations, health
systems, pharmacy benefit managers and the public sector. The company operates
7,944 drugstores in all 50 states, the District of Columbia and Puerto Rico.
Take Care Health Systems is a Walgreens subsidiary that is the largest and
most comprehensive manager of worksite health and wellness centers and
in-store convenient care clinics, with more than 700 locations throughout the

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D)
research. Driven by passionate, grassroots volunteers connected to children,
adolescents, and adults with this disease, JDRF is the largest charitable
supporter of T1D research. The goal of JDRF is to improve the lives of all
people affected by T1D by accelerating progress on the most promising
opportunities for curing, better treating, and preventing T1D. JDRF
collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.6 billion to T1D
research. More than 80 percent of JDRF's expenditures directly support
research and research-related education. Past JDRF research efforts have
helped to significantly improve the care of people with this disease, and have
expanded the critical scientific understanding of T1D. JDRF will not rest
until T1D is fully conquered. For more information, please visit www.jdrf.org.


Website: http://www.jdrf.org
Contact: William Sorensen, +1-212-479-7558, wsorensen@jdrf.org
Press spacebar to pause and continue. Press esc to stop.